Ipsen Biopharmaceuticals, Inc. drugs

7 results

  • bylvay

    (odevixibat)
    Ipsen Biopharmaceuticals, Inc.
    BYLVAY is indicated for treating pruritus in patients 3 months and older with Progressive Familial Intrahepatic Cholestasis (PFIC) and cholestatic pruritus in patients 12 months and older with Alagille Syndrome (ALGS). Note: it may not be effective for all PFIC type 2 patients.
    Medication Details
    Drug Interactions

  • increlex

    (mecasermin)
    Ipsen Biopharmaceuticals, Inc.
    INCRELEX is indicated for treating growth failure in pediatric patients aged 2 and older with severe primary IGF-1 deficiency or growth hormone gene deletion and neutralizing antibodies to GH. It is not a substitute for growth hormone and is not intended for secondary IGF-1 deficiencies.
    Medication Details
    Drug Interactions

  • iqirvo

    (elafibranor)
    Ipsen Biopharmaceuticals, Inc.
    IQIRVO is indicated for treating primary biliary cholangitis (PBC) in adults, used with ursodeoxycholic acid (UDCA) for those with inadequate response or as monotherapy for those intolerant to UDCA. Its approval is based on alkaline phosphatase reduction, not demonstrated improvement in survival or liver events.
    Medication Details
    Drug Interactions

  • onivyde

    (IRINOTECAN HYDROCHLORIDE)
    Ipsen Biopharmaceuticals, Inc.
    ONIVYDE is indicated for use in combination with other medications for treating metastatic pancreatic adenocarcinoma in adults, both as a first-line treatment and after progression on gemcitabine-based therapy. It is not approved as a standalone treatment for this condition.
    Medication Details
    Drug Interactions

  • sohonos

    (palovarotene)
    Ipsen Biopharmaceuticals, Inc.
    SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), specifically in females aged 8 years and older and males aged 10 years and older.
    Medication Details
    Drug Interactions

  • somatuline depot

    (lanreotide acetate)
    Ipsen Biopharmaceuticals, Inc.
    SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.
    Medication Details
    Drug Interactions